Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features

The possibilities of treatment of patients with metastatic non-small cell lung cancer have significantly expanded in the recent years. Several combined regimens of chemoimmunotherapy are currently being proposed as the first line, some patients with PD-L1 overexpression may be prescribed pembrolizum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena V. Reutova, Konstantin K. Laktionov
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	non-small cell lung cancer adenocarcinoma chemotherapy immunotherapy angiogenesis inhibitors docetaxel nintedanib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/445a66ac50844b09a5bc2e205b4eef57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:445a66ac50844b09a5bc2e205b4eef57
record_format	dspace
spelling	oai:doaj.org-article:445a66ac50844b09a5bc2e205b4eef572021-11-30T16:55:01ZAntiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features1815-14341815-144210.26442/18151434.2021.3.201138https://doaj.org/article/445a66ac50844b09a5bc2e205b4eef572021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/80647/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The possibilities of treatment of patients with metastatic non-small cell lung cancer have significantly expanded in the recent years. Several combined regimens of chemoimmunotherapy are currently being proposed as the first line, some patients with PD-L1 overexpression may be prescribed pembrolizumab or atezolizumab in monotherapy. Standard platinum-containing chemotherapy (PCT) has lost its position and is relevant only for contraindications to immuno-oncological (IO) drugs. The change in the standart of the first line inevitably led to the search for new optimal modes of the second line. The strategy of "angio-immunogenic switching" is promising after progression on the regimens with IO, anti-angiogenic drugs are used. Nintedanib a multikinase angiogenesis inhibitor in combination with docetaxel is a standard second-line therapy option in patients with lung adenocarcinoma after progression on PCT. The effectiveness of this regimen is being studied in a prospective non-interventional VARGADO study. The patients were divided into 3 cohorts, depending on which regimen was used earlier one line of PCT or PCT, followed by IO or chemoimmunotherapy. The results showed that the combination of docetaxel + nintedanib was effective both as a third line (after PCT and IO), and in the second after chemoimmunotherapy. The research is ongoing.Elena V. ReutovaKonstantin K. LaktionovIP Habib O.N.articlenon-small cell lung canceradenocarcinomachemotherapyimmunotherapyangiogenesis inhibitorsdocetaxelnintedanibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 425-427 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-small cell lung cancer adenocarcinoma chemotherapy immunotherapy angiogenesis inhibitors docetaxel nintedanib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer adenocarcinoma chemotherapy immunotherapy angiogenesis inhibitors docetaxel nintedanib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Elena V. Reutova Konstantin K. Laktionov Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
description	The possibilities of treatment of patients with metastatic non-small cell lung cancer have significantly expanded in the recent years. Several combined regimens of chemoimmunotherapy are currently being proposed as the first line, some patients with PD-L1 overexpression may be prescribed pembrolizumab or atezolizumab in monotherapy. Standard platinum-containing chemotherapy (PCT) has lost its position and is relevant only for contraindications to immuno-oncological (IO) drugs. The change in the standart of the first line inevitably led to the search for new optimal modes of the second line. The strategy of "angio-immunogenic switching" is promising after progression on the regimens with IO, anti-angiogenic drugs are used. Nintedanib a multikinase angiogenesis inhibitor in combination with docetaxel is a standard second-line therapy option in patients with lung adenocarcinoma after progression on PCT. The effectiveness of this regimen is being studied in a prospective non-interventional VARGADO study. The patients were divided into 3 cohorts, depending on which regimen was used earlier one line of PCT or PCT, followed by IO or chemoimmunotherapy. The results showed that the combination of docetaxel + nintedanib was effective both as a third line (after PCT and IO), and in the second after chemoimmunotherapy. The research is ongoing.
format	article
author	Elena V. Reutova Konstantin K. Laktionov
author_facet	Elena V. Reutova Konstantin K. Laktionov
author_sort	Elena V. Reutova
title	Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
title_short	Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
title_full	Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
title_fullStr	Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
title_full_unstemmed	Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
title_sort	antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/445a66ac50844b09a5bc2e205b4eef57
work_keys_str_mv	AT elenavreutova antiangiogenictherapyinpretreatedpatientswithlungadenocarcinomawithoutactivatingmutationsnewfeatures AT konstantinklaktionov antiangiogenictherapyinpretreatedpatientswithlungadenocarcinomawithoutactivatingmutationsnewfeatures
_version_	1718406441010724864

Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features

Ejemplares similares